Research / HBIO / Fundamental state Inspectable configuration
State dimensions Filing 0001171843-24-001239 General Corporate
Debt relative to revenue RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.debt_to_revenue
32.57% · OPTIONAL · NOT_ENOUGH_HISTORY
Capex intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.capex_revenue_ratio
1.59% · OPTIONAL · NOT_ENOUGH_HISTORY
Operating cash generation RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
12.50% · OPTIONAL · NOT_ENOUGH_HISTORY
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
-0.96% · CORE · NOT_ENOUGH_HISTORY
Inventory pressure RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
22.02% · OPTIONAL · NOT_ENOUGH_HISTORY
Gross margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.gross_margin
58.86% · CORE · NOT_ENOUGH_HISTORY
Operating margin RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.operating_margin
1.69% · CORE · NOT_ENOUGH_HISTORY
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
10.48% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity RAW Current state valid · history insufficient
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
4.45% · OPTIONAL · NOT_ENOUGH_HISTORY
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 16 states History building
Sep 30, 2022 0/8 normalized Level 3 Dec 31, 2022 0/8 normalized Level 3 Mar 31, 2023 0/8 normalized Level 3 Jun 30, 2023 0/8 normalized Level 3 Sep 30, 2023 0/9 normalized Level 3 Dec 31, 2023 0/9 normalized Level 3 Mar 31, 2024 0/9 normalized Level 3 Jun 30, 2024 0/9 normalized Level 3 Sep 30, 2024 8/9 normalized Level 3 Dec 31, 2024 8/9 normalized Level 3 Mar 31, 2025 8/9 normalized Level 3 Jun 30, 2025 8/9 normalized Level 3 Sep 30, 2025 9/9 normalized Level 3 Dec 31, 2025 9/9 normalized Level 3 Mar 31, 2026 9/9 normalized Level 3 Jun 30, 2026 9/9 normalized Level 3 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 152.75%
Current 32.57%
Delta -120.18% Capex Intensity Increased
Previous 0.86%
Current 1.59%
Delta 0.74% Cash Generation Decreased
Previous 17.19%
Current 12.50%
Delta -4.70% Growth Increased
Previous -5.79%
Current -0.96%
Delta 4.83% Inventory Pressure Decreased
Previous 101.79%
Current 22.02%
Delta -79.78% Margin Increased
Previous 58.06%
Current 58.86%
Delta 0.80% Profitability Increased
Previous -3.68%
Current 1.69%
Delta 5.37% R And D Intensity Decreased
Previous 10.88%
Current 10.48%
Delta -0.40% Sbc Intensity Decreased
Previous 5.37%
Current 4.45%
Delta -0.92% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.